MX2009005381A - Vacuna para leishmania canina. - Google Patents

Vacuna para leishmania canina.

Info

Publication number
MX2009005381A
MX2009005381A MX2009005381A MX2009005381A MX2009005381A MX 2009005381 A MX2009005381 A MX 2009005381A MX 2009005381 A MX2009005381 A MX 2009005381A MX 2009005381 A MX2009005381 A MX 2009005381A MX 2009005381 A MX2009005381 A MX 2009005381A
Authority
MX
Mexico
Prior art keywords
leishmania vaccine
canine
leishmania
compositions
methods
Prior art date
Application number
MX2009005381A
Other languages
English (en)
Inventor
Laurent Bernard Fischer
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of MX2009005381A publication Critical patent/MX2009005381A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona vectores que contienen y expresan KMP11 de Leishmania in vivo o un epítope del mismo que induce una respuesta inmune en un perro contra Leishmania, composiciones que comprenden los vectores, métodos de vacunación contra Leishmania y equipos para el uso con tales métodos y composiciones.
MX2009005381A 2006-11-21 2007-11-19 Vacuna para leishmania canina. MX2009005381A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86684806P 2006-11-21 2006-11-21
PCT/US2007/085142 WO2008064181A2 (en) 2006-11-21 2007-11-19 Prime boost canine leishmania vaccine

Publications (1)

Publication Number Publication Date
MX2009005381A true MX2009005381A (es) 2009-06-30

Family

ID=39430543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005381A MX2009005381A (es) 2006-11-21 2007-11-19 Vacuna para leishmania canina.

Country Status (11)

Country Link
US (2) US7794736B2 (es)
EP (1) EP2086580A2 (es)
AR (1) AR063882A1 (es)
BR (1) BRPI0719078A2 (es)
CA (1) CA2670097C (es)
IL (1) IL198897A (es)
MA (1) MA31014B1 (es)
MX (1) MX2009005381A (es)
TN (1) TN2009000195A1 (es)
TW (1) TWI478723B (es)
WO (1) WO2008064181A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012069A (es) * 2008-05-08 2010-12-14 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
BRPI0912768A2 (pt) * 2008-05-21 2016-05-17 Infectious Disease Res Inst vacinas de poliproteínas recombinante para o tratamento e diagnóstico de leishmaniose
GB0906906D0 (en) * 2009-04-23 2009-06-03 Univ York Nucleic acid molecule
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
WO2016073410A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615663B1 (de) * 2003-10-24 2007-12-26 Mologen AG Mittel zur behandlung von infektionen mit leishmanien
MX2007010073A (es) 2005-02-18 2007-10-10 Astrazeneca Ab Metodo para determinar la respuesta de los inhibidores de chk1.
EP3147296A1 (en) * 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US8524677B2 (en) * 2006-03-13 2013-09-03 Council Of Scientific And Industrial Research DNA vaccine as immunoprophylaxis against Kala-azar

Also Published As

Publication number Publication date
TWI478723B (zh) 2015-04-01
TW200826958A (en) 2008-07-01
IL198897A (en) 2013-08-29
MA31014B1 (fr) 2009-12-01
AR063882A1 (es) 2009-02-25
US7794736B2 (en) 2010-09-14
IL198897A0 (en) 2011-08-01
EP2086580A2 (en) 2009-08-12
US20080241193A1 (en) 2008-10-02
BRPI0719078A2 (pt) 2013-12-03
US20100285066A1 (en) 2010-11-11
US8871225B2 (en) 2014-10-28
TN2009000195A1 (en) 2010-10-18
WO2008064181A2 (en) 2008-05-29
CA2670097A1 (en) 2008-05-29
CA2670097C (en) 2015-10-06
WO2008064181A3 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
EP2468776A3 (en) Anti-Robo4 antibodies and uses therefor
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
HN2012001223A (es) Antagonistas de pcsk 9
MX2011004219A (es) Vacuna contra el virus de la peste equina africana.
MX2009005381A (es) Vacuna para leishmania canina.
TW200806316A (en) Yeast-based vaccine for inducing an immune response
GB201009273D0 (en) Novel vaccine
PH12014501835A1 (en) Novel adjuvant compositions
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
EA201100268A1 (ru) Вакцина
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2006122223A3 (en) Strategies for delivery of active agents using micelles and particles
EP2468772A3 (en) Antibodies to EGFL7 and methods for their use
IN2014CN03454A (es)
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
MX348137B (es) Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
WO2007024947A3 (en) Canine influenza vaccines
IN2014CN00547A (es)
MX2013013812A (es) Vacunas geneticas contra el virus hendra y el virus nipah.
GB0703976D0 (en) Liposome preparation
MX2010008170A (es) Vacunas para influenza canina.
NZ629420A (en) Sheep nematode vaccine
TN2010000500A1 (en) Leishmania vaccine using sand fly salivary immunogen
WO2008142483A3 (en) Vaccine compositions and methods of use thereof
AU2019268149A1 (en) Live attenuated heterologous vaccine for Leptospira

Legal Events

Date Code Title Description
FG Grant or registration